Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel)
Bristol Myers Squibb announced that the European Commission (EC) has granted Conditional Marketing Authorization for Abecma (idecabtagene vicleucel; ide-cel), a first-in-class B-cell…
Read More...
Read More...
